| Expression pattern: |
UP |
| Associated gene: |
FMR1, PDHA1 |
| Associated microRNA: |
- |
| Biological function: |
Promotes tumour growth, proliferation and invasion; enhances mitochondrial respiration and ARSI sensitivity modulation (knockdown increases sensitivity). |
| Molecular mechanism: |
m6A-modified circRBM33 forms a binary complex with FMR1, binds PDHA1 mRNA and sustains PDHA1 mRNA stability, thereby activating mitochondrial metabolism/respiration. |
| Biological pathway or process: |
mitochondrial function (promotes); oxidative phosphorylation (promotes); proliferation (promotes); invasion (promotes); drug resistance (inhibits) |
| Detected method: |
Q
S
|
| Validation methods: |
Back-Splice Junction PCR / divergent primers PCR; RNase R Treatment; Sanger Sequencing; Actinomycin D / DRB Stability Assay; RT-qPCR; MeRIP / MeRIP-seq; Nuclear-Cytoplasmic Fractionation; FISH / smFISH; RIP (RNA Immunoprecipitation); RNA Pull-Down; Western Blot; Transfection; CCK8; Colony Formation Assay; Transwell Assay; In Vivo Animal Model; IHC (Immunohistochemistry); H&E Staining; ELISA; Bioinformatics Analysis; Survival Analysis |
| Clinical significance: |
High expression of circRBM33 predicts poor biochemical recurrence (BCR)-free survival and correlates with Gleason score. |
| Description: |
circRBM33 (hsa_circ_0001771) is up-regulated and m6A-modified in prostate cancer. It promotes proliferation, invasion, and xenograft tumour growth by forming an m6A-dependent complex with FMR1 that stabilizes PDHA1 mRNA and enhances mitochondrial respiration/oxidative phosphorylation. circRBM33 depletion improves sensitivity to ARSI therapy (enzalutamide/darolutamide) and high circRBM33 predicts worse BCR-free survival. |
| Confidence score: |
0.8794 |